Cancer is a disease of mutations, but what does that really mean?

Cancer is caused by the alterations in our genes that ultimately control the way our cells function. Our cells are constantly changing and dividing, and through these processes, can sometimes become dangerously mutated. However, many cancers are treatable and can be controlled with therapies specific to your own tumor mutations.

How do I determine which treatment path is best-suited for my cancer?

In order to determine your optimal treatment plan, it is important to identify your specific cancer mutations through a next-generation sequencing (NGS) test.

This is a simple procedure that requires blood work or a tissue sample. A specialized lab analyzes these samples to fully sequence a large variety of mutations in your body. NGS testing is often encouraged in advanced cancer patients, and it represents a crucial step in delivering personalized medicines to patients – which is exactly what we are striving to accomplish here at Endeavor.

I’m ready to take an NGS test. How should I proceed?

Discuss NGS testing with your healthcare provider to ensure that this is the right step for you.

Endeavor is partnered with xCures. Endeavor is currently looking at the PTCH1-LOF mutation. Regardless of your eligibility for the Endeavor trial, xCures will still send you a list of other treatment options that could work for your cancer mutation. This means that even if you are not eligible for the Endeavor trial, you will receive a list of other treatment options that could work against your cancer mutation.

Patient Education

At Endeavor, we believe that advocating for yourself as a patient is important. Here are some tools to help get you started. As always, we encourage discussing any and all information provided below with your doctor.

xCures Target Cancer Podcast


Oncology FAQ


Do You Qualify?


What help can Endeavor offer?

Currently, Endeavor is conducting a Phase 2 clinical trial to study our investigational therapy, ENV-101, in patients with a PTCH1-loss-of-function (LoF) mutation.

Enrollment for this trial is currently closed. If you are interested in more information please contact EBMClinical@endeavorbiomedicines.com.